June 19, 2025

Ropeginterferon Alfa-2b Outperforms Anagrelide as Second-Line Therapy for ET, Study Finds

Ropeginterferon alfa-2b demonstrated superior efficacy and safety compared with anagrelide as second-line therapy for patients with essential thrombocythemia (ET) who were intolerant or resistant to h...

The ASCO Post

June 17, 2025

Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment

In this installment of The ASCO Post’s Living a Full Life series, Stephen R. Grobmyer, MD, FACS, speaks about his clinical and research career in oncology, the challenges and rewards of moving to Abu ...

The ASCO Post

June 17, 2025

Aconitine Tames Joints, Protects Bone

At EULAR 2025, researchers presented data showing aconitine reduced bone erosion and increased regulatory T cells in a rheumatoid arthritis mouse model.

Conexiant

June 16, 2025

How Does Medicaid Expansion Affect Access to Care in Patients With NSCLC?

Medicaid expansion was associated with a 2.8% increase in lung cancer surgeries performed and a 2.1% increase in surgeries completed within 90 days of diagnosis at high-volume hospitals.

The ASCO Post

June 16, 2025

Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer

The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed mono...

The ASCO Post

June 16, 2025

Some Patients With Advanced NSCLC Experience Durable Disease Control After Immunotherapy Discontinuation

A subset of patients with advanced non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitors due to immune-related adverse events continued to experience long-term disease contr...

The ASCO Post

June 16, 2025

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation,...

The ASCO Post

June 16, 2025

Extensive-Stage SCLC: Lurbinectedin and Atezolizumab

Results from the global phase III IMforte trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some p...

The ASCO Post

June 16, 2025

Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations

In an interim analysis of a Japanese trial (ACHILLES/TORG1834) reported in the Journal of Clinical Oncology, Miura et al evaluated whether afatinib prolonged progression-free survival vs platinum-base...

The ASCO Post